๋ผ๋ฐํฌ์ฌ๋
**๋ผ๋ฐํฌ์ฌ๋(Rabacfosadine)**์ ์ฃผ๋ก ๊ฐ ๋ฆผํ์ข (B์ธํฌ ๋ฐ T์ธํฌ)๊ณผ ๋ค๋ฐ์ฑ ๊ณจ์์ข ์น๋ฃ์ ์ฌ์ฉ๋๋ ์๋ก์ด ํญ์ข ์์ ์ ๋๋ค. > **์์ ๊ฒฝ๊ณ :** ์ด ์ฝ๋ฌผ์ ๊ฐ๋ ฅํ ์ธํฌ๋ ์ฑ ์ฝ๋ฌผ์ ๋๋ค. ์๊ฒฉํ ํํ์๋ฒ ์์ ์ง์นจ์ ๋ฐ๋ผ ํ๋ จ๋ ์ ๋ฌธ๊ฐ๋ง์ด ์กฐ์ ๋ฐ ํฌ์ฌํด์ผ ํฉ๋๋ค.
์์ฉ ๊ธฐ์ : Rabacfosadine is a **prodrug** of the nucleotide analogue **PMEG** (9-(2-phosphonylmethoxyethyl)guanine). Once converted, it acts by **inhibiting DNA polymerases** โ preventing DNA synthesis โ causing **cytotoxicity** and apoptosis in rapidly dividing cells, such as neoplastic lymphocytes.
๋๋ฌผ ์ข ๋ณ ์ฉ๋
- Lymphoma (B and T cell) and multiple myeloma ยท 0.82-1 mg/kg ยท IV ยท once every 21 days ยท over 30 min ยท Has been used in combination with doxorubicin at weeks 0, 6, 12 as part of an alternating protocol.
์ฉ๋์ ๋ฉดํ ์์ ์ ๋ฌธ๊ฐ๋ฅผ ์ํ ์์ ์ฐธ๊ณ ์๋ฃ์ ๋๋ค. ํญ์ ์ต์ ๋ผ๋ฒจ๊ณผ ๊ฐ๋ณ ํ์์ ๋ํด ํ์ธํ์ญ์์ค.
ํฌ์ฌ ๊ฒฝ๋ก
๊ธ๊ธฐ
- Known hypersensitivity
- Pre-existing bone marrow suppression
- Liver dysfunction
- Known pulmonary disease
- Susceptibility to pulmonary fibrosis
์ด์๋ฐ์
- Myelosuppression
- Gastrointestinal adverse events (including haemorrhagic gastroenteritis)
- Liver enzyme activity elevation
- Azotaemia
- Fever
- Weight loss
- Lethargy
- Dermatological signs
- Pulmonary fibrosis
- Injected sclera
- Urinary signs (proteinuria, glycosuria)
๋ชจ๋ํฐ๋ง
- Complete Blood Count (CBC) for myelosuppression
- Liver enzyme activity
- Renal parameters (BUN, Creatinine) and Urinalysis (for proteinuria/glycosuria)
- Respiratory rate and effort (monitor for pulmonary fibrosis)
- Clinical signs of gastrointestinal toxicity
๊ณผ์ฉ๋
Information not provided in the monograph. Due to its cytotoxic nature, overdose is likely to cause severe myelosuppression, gastrointestinal toxicity, and potentially fatal pulmonary fibrosis. Aggressive supportive care and monitoring are indicated.
VetSheet ์ฝ๋ฌผ ๋ ํผ๋ฐ์ค๋ ๋ฉดํ ์์ ์ ๋ฌธ๊ฐ๋ฅผ ์ํ ์์ ์์ฌ๊ฒฐ์ ๋ณด์กฐ ๋๊ตฌ์ด๋ฉฐ, ์ ๋ฌธ์ ํ๋จ์ด๋ ์ ์กฐ์ฌ์ ์ต์ ๋ผ๋ฒจ์ ๋์ ํ์ง ์์ต๋๋ค.